Linked Life Data

15481570

Source:http://linkedlifedata.com/resource/pubmed/id/15481570

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
30
pubmed:dateCreated
2004-10-14
pubmed:abstractText
Large-scale trials have shown that primary prevention using acetylsalicylic acid is useful in all patients with a cardiovascular risk exceeding 1.5% annually. In these patients the benefits of prevention outweigh the risks of bleeding. Almost all patients with diabetes mellitus are at high risk of developing cardiovascular disease. Additionally, most diabetics have other cardiovascular risks besides diabetes, providing further argument for prevention with acetylsalicylic acid. Only very few prospective trials have confirmed that acetylsalicylic acid treatment in patients with diabetes mellitus reduces their risk of cardiovascular disease and myocardial infarction. Treatment with acetylsalicylic acid should be considered in all patients with diabetes, especially in view of their decreased survival after a cardiovascular event, myocardial infarction in particular. If acetylsalicylic acid is contra-indicated treatment with clopidogrel is an alternative.
pubmed:commentsCorrections
pubmed:language
dut
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0028-2162
pubmed:author
pubmed:issnType
Print
pubmed:day
24
pubmed:volume
148
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1481-5
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
[Acetylsalicylic acid for the primary prevention of cardiovascular disease in diabetic patients].
pubmed:affiliation
Universitair Medisch Centrum Utrecht, afd. Interne Geneeskunde, Heidelberglaan 100, 3584 CX Utrecht.
pubmed:publicationType
Journal Article, English Abstract, Review